{
    "Sponsor": "Amgen Inc.",
    "Study Number": "CC-10004-PSOR-020",
    "Protocol Version and Date": "Amendment 3 FINAL: 01 May 2020",
    "Study Title": "A PHASE 4, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE IMPACT OF APREMILAST (CC-10004) ON QUALITY OF LIFE, EFFICACY, AND SAFETY IN SUBJECTS WITH MANIFESTATIONS OF PLAQUE PSORIASIS AND IMPAIRED QUALITY OF LIFE",
    "Project Title": "CC-10004-PSOR-020",
    "Phase": "Phase 4",
    "Therapeutic Area": "Plaque Psoriasis",
    "Number of Patients (if known)": "255",
    "Number of Sites (if known)": "Not Available",
    "Indication": "Moderate to severe plaque psoriasis",
    "Duration of Treatment": "52 weeks",
    "Schedule of Assessments": "Table 5 (Schedule of Events)",
    "questionnaires": [
        {
            "longName": "Dermatology Life Quality Index",
            "shortName": "DLQI",
            "type": "PRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Screening",
                "Placebo-Controlled Phasea",
                "3",
                "4",
                "5",
                "Apremilast Extension Phaseb",
                "7",
                "9/ETc"
            ]
        },
        {
            "longName": "Static Physicians Global Assessment of Visible Locations",
            "shortName": "sPGA",
            "type": "ClinRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Screening",
                "Placebo-Controlled Phasea",
                "3",
                "4",
                "5",
                "Apremilast Extension Phaseb",
                "7",
                "9/ETc"
            ]
        },
        {
            "longName": "Scalp Physician Global Assessment",
            "shortName": "ScPGA",
            "type": "ClinRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Screening",
                "Placebo-Controlled Phasea",
                "3",
                "4",
                "5",
                "Apremilast Extension Phaseb",
                "7",
                "9/ETc"
            ]
        },
        {
            "longName": "Nail Psoriasis Severity Index",
            "shortName": "NAPSI",
            "type": "ClinRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Placebo-Controlled Phasea",
                "3",
                "4",
                "5",
                "Apremilast Extension Phaseb",
                "7",
                "9/ETc",
                "Screening"
            ]
        },
        {
            "longName": "Modified Static Physicians Global Assessment of Genitalia",
            "shortName": "Modified sPGA-G",
            "type": "ClinRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Screening",
                "Placebo-Controlled Phasea",
                "3",
                "4",
                "5",
                "Apremilast Extension Phaseb",
                "7",
                "9/ETc"
            ]
        },
        {
            "longName": "Palmoplantar Psoriasis Physicians Global Assessment",
            "shortName": "PPPGA",
            "type": "ClinRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Screening",
                "Placebo-Controlled Phasea",
                "3",
                "4",
                "5",
                "Apremilast Extension Phaseb",
                "7",
                "9/ETc"
            ]
        },
        {
            "longName": "Itch Numeric Rating Scale",
            "shortName": "NRS",
            "type": "PRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Placebo-Controlled Phasea",
                "3",
                "4",
                "5",
                "Apremilast Extension Phaseb",
                "7",
                "9/ETc"
            ]
        },
        {
            "longName": "Skin Discomfort/Pain Visual Analog Scale",
            "shortName": "VAS",
            "type": "PRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Placebo-Controlled Phasea",
                "3",
                "4",
                "5",
                "Apremilast Extension Phaseb",
                "7",
                "9/ETc"
            ]
        },
        {
            "longName": "Body Surface Area",
            "shortName": "BSA",
            "type": "None",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Placebo-Controlled Phasea",
                "3",
                "4",
                "5",
                "Apremilast Extension Phaseb",
                "7",
                "9/ETc"
            ]
        },
        {
            "longName": "Psoriasis Area Severity Index",
            "shortName": "PASI",
            "type": "ClinRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Placebo-Controlled Phasea",
                "3",
                "4",
                "5",
                "Apremilast Extension Phaseb",
                "7",
                "9/ETc",
                "Screening"
            ]
        },
        {
            "longName": "Patient Benefit Index",
            "shortName": "PBI",
            "type": "PRO",
            "questionnaireSchedule": "Post-treatment and follow-up as per Table 3",
            "questionnaireTiming": [
                "4",
                "5",
                "7",
                "9/ETc"
            ]
        },
        {
            "longName": "European Quality of Life 5-Dimension Questionnaire",
            "shortName": "EQ-5D",
            "type": "PRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Placebo-Controlled Phasea",
                "5",
                "9/ETc"
            ]
        },
        {
            "longName": "Work Productivity and Activity Impairment Questionnaire: Psoriasis",
            "shortName": "WPAI: PSO",
            "type": "PRO",
            "questionnaireSchedule": "Screening, baseline, and other visits as per Table 3",
            "questionnaireTiming": [
                "Placebo-Controlled Phasea",
                "5",
                "9/ETc"
            ]
        }
    ]
}